1. Home
  2. MTN vs DFTX Comparison

MTN vs DFTX Comparison

Compare MTN & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vail Resorts Inc.

MTN

Vail Resorts Inc.

N/A

Current Price

$156.74

Market Cap

5.2B

ML Signal

N/A

Logo Definium Therapeutics Inc. Common Shares

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$34.66

Market Cap

5.9B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
MTN
DFTX
Founded
1997
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
5.2B
5.9B
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
MTN
DFTX
Price
$156.74
$34.66
Analyst Decision
Hold
Strong Buy
Analyst Count
15
19
Target Price
★ $148.36
$72.78
AVG Volume (30 Days)
542.9K
★ 1.7M
Earning Date
12-09-2026
11-09-2026
Dividend Yield
★ 5.55%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 4.12
N/A
Revenue
★ $2,838,204,000.00
N/A
Revenue This Year
$7.02
N/A
Revenue Next Year
$3.71
N/A
P/E Ratio
$38.83
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$118.51
$14.62
52 Week High
$163.99
$49.70

Technical Indicators

Market Signals
Indicator
MTN
DFTX
Relative Strength Index (RSI) 57.94 47.64
Support Level $123.48 $32.43
Resistance Level $160.49 $38.59
Average True Range (ATR) 4.63 2.11
MACD 0.38 0.01
Stochastic Oscillator 61.08 46.71

Price Performance

Historical Comparison
MTN
DFTX

About MTN Vail Resorts Inc.

Vail Resorts Inc Bhd is a resorts and casinos company that operates mountain resorts and ski areas. The company has three business segments that include Mountain, Lodging, and Real Estate. The Mountain segment operates numerous ski resort properties that offer a variety of winter and summer activities, such as skiing, snowboarding, snowshoeing, hiking, and mountain biking. The Lodging segment owns and operates hotels and condominiums. The Real Estate segment owns, develops, and leases real estate, typically near its other properties. The company generates the vast majority of its revenue within the United States.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Share on Social Networks: